12:00 AM
Sep 15, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PC-DAC:Exendin-4: Completed Phase II enrollment

ConjuChem Biotechnologies Inc. (TSX:CJB), Montreal, Quebec
Product: PC-DAC:Exendin-4 ( CJC-1134-PC)
Business: Endocrine
Molecular target: Not applicable
Description: Exendin-4 created through preformed conjugate-drug affinity...

Read the full 108 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >